Note: This is sponsored content. The views expressed here are solely those of the author. Top News of the Day ...

FDA accepted Replimune’s resubmitted Biologics License Application for RP1 combined with Bristol Myers Squibb’s Opdivo to treat advanced melanoma The agency set April 10, 2026 as the decision deadline ...

Following a ~39% drop in the previous session, Replimune (NASDAQ:REPL) shares continued to trade lower on Friday as J.P. Morgan downgraded the stock to Underweight from Neutral, citing further ...

The fate of a once-promising cancer treatment now looks uncertain at best. The meeting was conducted with U.S. Food and Drug Administration (FDA) officials, and it took place on Tuesday. The subject ...

On July 22, 2025, Replimune revealed that the FDA had issued a Complete Response Letter (CRL) for its Biologics License Application for RP1, a novel immunotherapy aimed at treating advanced melanoma.

Ever wondered how JavaScript really works? In this video, we break down the computer science behind the world’s most popular programming language - from source code to execution? Learn how the engine ...

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company’s business, ...

On Monday, Replimune Group Inc. (NASDAQ:REPL) is reeling after the FDA unexpectedly rejected its skin cancer treatment, triggering a stock plunge and a wave of investor outrage. Shares fell sharply ...

Ever wondered how JavaScript was created and how it became the world’s most popular programming language?From its early days in Netscape to powering modern web apps, servers, and beyond, this video ...